Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,796 people get SNY articles and Market Currents by email alert.
Get email alerts on SNY »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Aubagio EU Backing Comes With Generic WorriesEP Vantage • Mon, Mar 25 -
-
-
-
-
New Reasons To Be Bullish On SanofiTrading Maven • Tue, Nov 6, 2012 -
-
-
-
-
Sanofi Challenges Novartis For Multiple Sclerosis Market ShareTodd Campbell • Thu, Sep 13, 2012 -
-
-
-
-
-
-
-
-
-
Sanofi Management Discusses Q3 2012 Results - Earnings Call TranscriptThu, Oct 25, 2012 • 1 Comment
-
Sanofi Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Sanofi's CEO Discusses Q4 2011 Results - Earnings Call TranscriptWed, Feb 8, 2012
-
Sanofi's CEO Discusses Q3 2011 Results - Earnings Call TranscriptSat, Nov 5, 2011
-
sanofi-aventis CEO Discusses Q2 2011 Results - Earnings Call TranscriptThu, Jul 28, 2011
-
Sanofi-Aventis CEO Discusses Q1 2011 Results - Earnings Call TranscriptThu, Apr 28, 2011
-
Genzyme Corporation CEO Discusses Q3 2010 Earnings - Call TranscriptWed, Oct 20, 2010
-
Genzyme Corporation Q2 2010 Earnings Call TranscriptWed, Jul 21, 2010
-
Genzyme Corporation Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
Genzyme Corporation Q4 2009 Earnings Call TranscriptWed, Feb 17, 2010
-
Sanofi-Aventis Q4 2009 Earnings Call TranscriptThu, Feb 11, 2010
-
at MarketWatch.com (May 9, 2013)
-
at CNBC.com (May 2, 2013)
-
at CNBC.com (May 2, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at MarketWatch.com (Apr 29, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at MarketWatch.com (Apr 15, 2013)
-
at CNBC.com (Apr 11, 2013)
-
at MarketWatch.com (Apr 2, 2013)
-
at CNBC.com (Mar 26, 2013)
-
at MarketWatch.com (Mar 26, 2013)
-
at MarketWatch.com (Mar 6, 2013)
-
at MarketWatch.com (Mar 4, 2013)
-
at MarketWatch.com (Feb 19, 2013)
-
at MarketWatch.com (Feb 11, 2013)
-
at CNBC.com (Feb 11, 2013)
-
at MarketWatch.com (Feb 11, 2013)
-
at CNBC.com (Feb 11, 2013)
-
at MarketWatch.com (Feb 5, 2013)
-
at CNBC.com (Feb 1, 2013)
SNY vs. ETF Alternatives
Company Description
We are a global biotechnology company dedicated to making a major impact on the lives of people with serious diseases. Our broad product and service portfolio is focused on rare genetic disease disorders, renal disease, orthopaedics, cancer, transplant and immune disease, and diagnostic and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, October 12, 2012, 4:24 PM Watson Pharmaceuticals (WPI) receives FDA approval on its Abbreviated New Drug Application for Irbesartan Tablets, a treatment for hypertension and diabetic nephropathy. Irbesartan is the generic equivalent to Sanofi's (SNY) Avapro. The company plans to begin shipping immediately. For the 12 months ending August 31, Avapro and its generic equivalents had total U.S. sales of approximately $390M. Comment! [Healthcare]
- Wednesday, October 3, 2012, 5:02 AM Bristol-Myers (BMY) is returning its share of global rights to blood thinner Plavix and blood pressure treatment Avalide to Sanofi (SNY) following the loss of patent protection for the drugs, although the American firm will retain U.S. and Puerto Rico rights to Plavix. BMY will receive royalties until 2018 and then a $200M terminal payment, although it's paying $80M to Sanofi over supply disruption to Avalide in the U.S. in 2011. (PR) Comment! [Healthcare]
- Tuesday, October 2, 2012, 3:11 PM Sanofi (SNY) acquires Columbian pharmaceuticals manufacturer Genfar S.A. for an undisclosed sum. Genfar is the second largest generic company in sales and leader in units in Colombia and has a commercial presence in Venezuela, Peru, Ecuador and ten other countries in Latin America. In 2011, its total sales were $133M, with 30% its receipts generated outside Colombia. The deal is expected to close in Q113. Comment! [Global & FX, Healthcare, M&A]
- Friday, September 28, 2012, 4:39 PM Sanofi (SNY) is initiating a voluntary recall of some lots of its Typhim Vi vaccine, saying they may be at risk for lower antigen content. The FDA notes, "There is no safety concern related to this action." Comment! [Healthcare]
- Thursday, September 20, 2012, 6:05 AM Ten major pharmaceutical firms, including AstraZeneca (AZN), Eli Lilly (LLY), GSK, J&J (JNJ) and Pfizer (PFE), have formed a non-profit organization called TransCelerate BioPharma to cooperate on research as they look to speed up drug development. TransCelerate will start by making clinical trials more efficient, including standardizing the way data is recorded to make it easier for regulators. Comment! [Healthcare]
- Thursday, September 13, 2012, 11:23 AM The FDA issues a warning that some consumers have reported receiving serious skin injuries while using certain over-the-counter mild muscle and joint pain relievers containing the active ingredients menthol, methyl salicylate and capsaicin. 43 reported cases of burns have been reported, with the injuries ranging from mild to severe chemical burns. Some of the products named include Sanofi's (SNY -0.1%) Icy Hot and Johnson & Johnson's (JNJ +0.7%) Bengay, among others. 2 Comments [Healthcare]
- Wednesday, September 12, 2012, 7:18 PM Sanofi (SNY) wins U.S. FDA approval for Aubagio, a pill designed to treat multiple sclerosis, making it the second oral therapy that will be available on the U.S. market. The drug will compete with Novartis' (NVS) Gilenya, an oral pill which was approved by the FDA in 2010. 1 Comment [Healthcare]
- Tuesday, September 4, 2012, 9:39 AM Impax Laboratories (IPXL) settles a lawsuit with Sanofi (SNY) unit Genzyme over two kidney disease drugs, with the latter agreeing to grant Impax a license to sell generic versions of Renvela and Renagel by mid-March 2014 and mid-September 2014 respectively. Last month Impax settled with Pfizer over bladder control treatment Detrol LA. (PR) 1 Comment [Healthcare]
- Tuesday, August 28, 2012, 9:27 AM Sanofi (SNY) has voluntarily recalled nine lots of Thymoglobulin, its drug for treating kidney rejection in transplant patients, after one of the lots failed a periodic stability test. The FDA says Sanofi, which carried out the recall earlier this month, has not learned of any safety problems connected to the failure. Comment! [Healthcare]
- Monday, August 27, 2012, 9:03 AM The FDA sends Genzyme a "refuse to file" letter in which it asks the Sanofi (SNY) unit to change the presentation of the data in a filing for the firm's Lemtrada treatment for multiple sclerosis so that the application is easier to navigate. The FDA has not requested additional data for further studies for Lemtrada, which could be launched in 2013 if the FDA approves it. (PR) Comment! [Healthcare]
- Thursday, August 23, 2012, 3:21 PM Regeneron (REGN +3.4%) spikes higher once again today on takeover chatter involving Sanofi (SNY -1%). A spokesperson for the company declined to comment, on any takeover talks, noting that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies. SNY is currently REGN's largest shareholder, with a standstill agreement in place that prevents SNY from acquiring more than 30% of REGN. Comment! [Healthcare, On the Move]
- Monday, August 13, 2012, 8:57 AM Sanofi (SNY) receives FDA approval for Auvi-Q for the emergency treatment of people who suffer severe allergic reactions, such as to nuts and insect bites. The product is an auto-injector "that talks users through each step" of the process. Sanofi has licensed the rights in N. America from Intelliject, which retains commercialization rights for the rest of the world. (PR) Comment! [Healthcare]
- Tuesday, August 7, 2012, 10:02 AM Eli Lilly's (LLY -2.2%) Forteo and risedronate, which is marketed by Warner Chilcott (WCRX +3.85%) and Sanofi (SNY +0.8%), go head to head in a Phase III trial of postmenopausal women with osteoporotic vertebral fractures and come out equal in the main goal of achieving a 30%+ fall in the worst back pain. (PR) Comment! [Healthcare]
- Friday, August 3, 2012, 2:36 PM Sanofi (SNY +4.8%) is higher today after the FDA approves Zaltrap, a drug developed by SNY and Regeneron Pharmaceuticals (REGN +1%) for the treatment of advanced colon cancer. Comment! [Healthcare, On the Move]
- Thursday, July 26, 2012, 12:18 PM More on Sanofi (SNY +3.2%) Q2: adjusted net profit -9.6% to €1.94B, hurt by patent expirations for Plavo and Avapro. Plans to announce details of job cuts at two French units in September, putting it on a collision course with the government, which says it won't tolerate job losses at profitable companies. Comment! [Earnings, On the Move, Healthcare]
- Thursday, July 26, 2012, 4:19 AM Sanofi (SNY): Q2 EPS of €1.48 beats by €0.09. Revenue of €8.87B (+6.2% Y/Y) beats by €0.23B. Shares +1.3% in Paris. (PR .pdf) Comment! [Earnings, Healthcare]
-
- View all 9 replies
-
-
-
- View all 1 replies
-
sstonerm3: Chines, since no one (shorts) is calling you out today, let me be the first. Congratulations on a good day's work.
-
- View all 3 replies
-
-
-
- View all 0 replies
-
- View all 4 replies
-
golfitobob: 33, TBT looks tempting,but,lots of bad EU to come.TLT should rally an give u a better entry in TBT -
inquisitivemind7: Lol, Doug Kass is getting increasingly bullish, he is also looking for a long TBT play.
-
- View all 17 replies
-
Brandon Gibbs: do you know if there is a good article explaining in detail, anywhere? -
-
- View all 9 replies
-
jason2788: quick, everyone write this down! god forbid he's not being truthful and forth coming about his trades. -
-
- View all 1 replies
-
-
- View all 10 replies
-
-
Mr. Massive: be careful next week chines - action packed - gdp revision, super debt comittee, euro stuff
-
- View all 0 replies
LATEST REPLIES